Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03802214 · ClinicalTrials.gov registry record
Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF（Tumor Necrosis Factor）Therapy
A clinical trial, sponsored by Stanford University.
- Terminated
- Registry status
- 1
- Enrollment target
NCT03802214: Clinical Trial study, sponsored by Stanford University.
NCT03802214 is a clinical trial that was terminated before completion, run by Stanford University. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03802214 was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
A case-control study to evaluate the immunoinflammatory effect of prior exposure to anti-TNF therapy in patients with ulcerative colitis starting vedolizumab therapy
Interventions
- DRUG Vedolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-10-29 |
| Est. Completion | 2020-12-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03802214
The ClinicalTrials.gov registry entry for NCT03802214 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vedolizumab is the first listed.
NCT03802214 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03802214 about?
NCT03802214 is a clinical study titled "Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF（Tumor Necrosis Factor）Therapy". A case-control study to evaluate the immunoinflammatory effect of prior exposure to anti-TNF therapy in patients with ulcerative colitis starting vedolizumab therapy
What is the current status of trial NCT03802214?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2020-10-29. Estimated completion is 2020-12-11.
What interventions are being tested in trial NCT03802214?
The interventions under investigation include: Vedolizumab (DRUG).
Who is sponsoring clinical trial NCT03802214?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.